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Organ transplantation became practical when long-term allograft sur-
vival was achieved in renal transplant recipients treated with a combination 
of azathioprine and prednisone." 28 The introduction of antilymphocyte 
globulin (ALG) as a short-term agent for the prevention or treatment of 
acute rejection further improved results,27 but the morbidity and mortality 
of cadaver renal transplantation remained significant. 14 
Advances in liver transplantation have closely paralleled events in the 
evolution of cadaveric kidney transplantation. From March 1, 1963, until 
February 29, 1980, 170 patients received liver transplants at the University 
of Colorado under conventional immunosuppression with azathioprine (or 
cyclophosphamide) and high-dose steroids, to which antilymphocyte glob-
ulin (ALG) was almost always added. 26 The 1- and 5-year survivals were 
32.9 per cent and 20.0 per cent, (Fig. 1). As of July 1, 1985, only 29 
patients (16.5 per cent) remained alive, including 14 adults and 15 children, 
10 of whom have survived 10 or more years. Transplantation of the liver 
with conventional immunosuppression was never able to achieve the success 
required to move it from the realm of experimental surgery to accepted 
clinical therapy. 
Cyclosporin-A (cyclosporine) was introduced to transplantation based 
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Figure 1. Survival of 170 liver transplant recipients trcated with conventional immuno-
suppression with azathioprine (or cyclophosphamide), high-dose steroids, and ALG between 
March 1, 1963, and Fcbruary 29, 1980, at the University of Colorado. 
011 the experimental work of Borel and colleagues I and the first clinical 
trials done by CaIne and associates. 2 A high patient mortality, a disquieting 
incidence of spontaneous lymphomas, and cyclosporine-induced nephrotox-
icity raised questions about the safety of the drug. Combination with low 
doses of prednisone permitted use of reduced doses of cyclosporine, with 
reduction in nephrotoxicity and patient mortality. IS, 23. 30 The lymphomas 
are now known to be associated with Epstein-Barr virus infection3 . 23. 29.m 
and to resolve when immunosuppression is withdrawn or reduced. 29 
Cyclosporine-steroid therapy was introduced to the liver transplant 
program at the University of Colorado on March 1, 1980, and continued 
when the program transferred to the University of Pittsburgh. From March 
1, 1980, through December 31, 1984, 313 patients, including 177 adults 
and 136 children, have received primary orthotopic liver transplants in the 
Colorado-Pittsburgh series under the cyclosporine-prednisone regimen. A 
clinical trial with OKT3 monoclonal antihody (Ortho Phannaeenticals, 
Haritan, New Jersey) for the treatment of aeute rejection began in October 
1984. One- and five-year actuarial survivals are 69.7 per cent and 62.8 per 
cent, respectively (Fig. 2). This dramatic improvement over results obtained 
with conventional immunosuppression has led to acceptance of liver trans-
plantation as a therapeutic operation 12 and has catalyzed a proliferation of 
liver transplant programs in the l' nitcd States and abroad. 25 
There have been changes in the indications for liver transplantation 
sinee the introduction of cyclosporine (Figs. 3 and 4).20 Biliary atresia has 
been the most common indication for liver replacement since 1980. In 
adults, primary biliary cirrhosis and sclerosing cholangitis are more common 
indications for liver transplantation, and alcoholic cirrhosis and primary 
liver tumors have declined. Acceptance of transplantation as the treatment 
of choice for nearly all causes ofliver failure has broadened patient selection 
and increased patient rcferral to the transplant center. 
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Figure 2. Survival (life table method) is shown for 313 liver transplant recipients treated 
with cyclosporine and low-dose steroids between March 1, 1980, and December 31, 1984, at 
the University of Colorado and the University of Pittsburgh. Treatment of acute rejection 
epidoses with OKT3 monoclonal antibody (Ortho Pharmaceuticals, Raritan, New Jersey) was 
begun in 1984. 
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Figure 3. Indications are shown fCir 170 liver transplants done with conventional 
immunosuppression (azathioprine and high-dose steroids) from March 1, 1963, to February 
29, 1980. Twenty-nine patients are still living. 
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Figure 4. Indications for liver transplantation are shown for 313 patienh treated with 
cyclosporine and low-dose steroids betwen March 1, 1980, and December 31, 1984. Two 
hundred nine patients are still living, including 106 of the 177 (.'59.9 per cent) adults and 103 
of the 136 (75.7 per cent) children in the series. 
BILIARY ATRESIA 
Biliary atresia has been the reason for transplantation in 72 (52.9 per 
cent) of the 136 children receiving transplants. Fifty-four of these children 
are alive at least 6 months after transplantation. One- and five-year actuarial 
patient survival rates are 76.2 per cent and 73.7 per cent, respectively (Fig. 
5). Patients operated on at age 2 years or less have not done as well as 
older patients. One- and five-year survival rates in these patients are 64.8 
per cent and 57.6 per cent, respectively. 
Biliary atresia is cured by liver transplantation, and the excellent 
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Figure 5. Actuarial !life table) survival after liver transplantation with cyclosporine and 
prednisone is shown IClr 72 patients with biliary atresia. Children under 2 years of age often 
receive transplants ill worse condition and with a higher incidence of technical complications 
than older children. 
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patient survival now obtainable makes liver replacement the treatment of 
choice for this disorder. The greatest problem limiting treatment of biliary 
atresia is the limited availability of very small pediatric donors. Most of the 
patients undergoing liver transplantation for biliary atresia have had at least 
one portoenterostomy (Kasai) procedure. A successful biliary diversion can 
stabilize the patient and buy valuable time. However, previous abdominal 
surgery, especially in the right upper quadrant, makes hepatectomy in a 
transplant recipient more difficult. A single biliary diversion procedure 
usually will not increase the risk of transplantation, but multiple attempts 
at revision of biliary drainage and the creation of stomas can make 
transplantation an arduous and dangerous undertaking. 
INBORN ERRORS OF METABOLISM 
Forty-three patients, including 29 children and 14 adults, have received 
liver transplants for correction of inborn errors of metabolism. Actuarial 
survivals at 1 and 5 years are both 74.4 per cent (Fig. 6). Twenty-three 
patients are living more than 1 year after surgery, and there have been no 
deaths after the first year. Most of these transplants were performed for 
cirrhosis related to the metabolic disorder. In general, these patients are 
excellent candidates for transplantation, as few have had previous surgery, 
and if the disease is detected carll' enough, the patients can receive the 
transplants before they devclop severe liver failure. 
Alpha-I-Antitrypsin Deficiency 
Twenty-seven patients have received transplants for alpha-I-antitrypsin 
deficiency. This disorder is associated with development of a progressive 
macronodular cirrhosis and obstructive pulmonary disease. Transplantation 
is curative and results in conversion of the PiZZ to PiM.'vI phenotype and 
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Figure 6. Actuarial (life table) survival is shown for 43 patients receiving liver transplants 
with cyclosporine and prednisone for inborn errors of metabolism. Except for patients in 
advanced hepatic failure with coma, survival for patients with this group of diseases has been 
excellent. 
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normalization of serum alpha-I-antitrypsin levels. Actuarial survival is 70.4 
per cent at both 1 and 5 years. Fourteen patients are living 1 year or more 
after operation, and there have been no deaths beyond 6 months after 
transplantation. 
Wilson's Disease 
Seven patients have received transplants for Wilson's disease, a disor-
der associated with reduced copper excretion, decreased serum cerulo-
plasm, and excessive copper deposition in both liver and brain. Five 
patients are surviving. Liver transplantation is curative and is indicated 
whcn hepatic involvement hecomes signficant. The first presentation of this 
illness can be acute hepatic failure and hemolytic crisis. It is best to allow 
recovery from the acute hemolytic crisis before proceeding with transplan-
tation, but recently a 13-year-old girl in irreversible acute hepatorenal 
failure underwent a successful transplant operation. Patients presenting in 
deep coma have the poorest prognosis. 
Tyrosinemia 
Hereditary tyrosinemia, which results in a progressive cirrhosis, ne-
cessitated transplantation in five patients, fom of whom remain alive 1.3 to 
44 months after surgery. The abnormal metabolic by-products of tyrosine 
are carcinogenic, and patients with tyrosinemia are at high risk of developing 
hepatocellular cancer. Transplantation should be performed before malig-
nanc\, develops. At the time of transplantation a 5-year-old boy with 
tyrosinemia was found to have a tumor extending into the portal vein. 
Although all gross tumor was removed at surgery and the patient received 
a course of chemotherapy postoperatively, he died from recurrent cancer 
within 8 months of transplantation. Apparently, the hepatocellular cancer 
can persist independent of the metabolic disorder. Nevertheless, all of the 
survivors had hepatomas that have not recurred. 
Other Metabolic Errors 
Two patients have received transplants for glycogen storage disease 
and two patients for hemochromatosis. All four patients arc living 8 to 41 
months following liver replacement. 
Recently a 12-year-old girl with homozygous familial hypercholestero-
lemia complicated by intractable angina and cardiac failure recei\eel a 
simultaneous heart and liver transplant. The heart transplant was perf()rmed 
to replace the severely damaged heart that had already undergone several 
surgical procedures. The liver, which was anatomically normal, was replaced 
to correct the underlying metabolic disorder. Now, more than 15 ll10nths 
after surgery, the patient has serum cholesterol levels that have remained 
less than 300 mg per dl compared with pretransplant levels of more than 
1000 mg per ell. Liver transplantation is likely to become the treatment of 
choice for many metabolic deficiencies that have their origin in the liver. 
CIRRHOSIS 
Seventy patients, including 13 children and 57 adults, have received 
liver transplants f()r postnecrotic cirrhosis. Most of these patients have the 
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Figure 7. Actuarial (life table) survival is shown for 70 patients receiving liver transplants 
with cyclosporine and prednisone for postnecrotic cirrhosis. Patients over 40 years of age have 
not done as well as younger patients. 
non A, non B variety of chronic hepatitis. One and five-year actuarial 
survivals are 62.8 per cent and .52.9 per cent. Children fare better than 
adults, and patients over 40 years of age have the worst prognosis (Fig. 7). 
Only 6 of the 16 patients over 40 survived the first year after transplantation. 
Five patients with positive serology for hepatitis B surface and E 
antigen were treated with human antihcpatitis B immune globulin and with 
Hcpatavax-B vaccine. All five patients either retained or reverted to their 
original hepatitis serology. Two of these patients have died with recurrent 
hepatitis. Although this is a limited experience, it suggests that patients 
with positive hepatitis B serology remain at significant risk of recurrence, 
especially if they hav~ E antigenemia. 
Two recent cases have further stimulated interest in transplantation 
for hepatitis. A 24-year-old surgical resident who contracted acute hepatitis 
from patient contact presented in severe hepatic failure and stage IV coma. 
An emergency liver transplant was performed, and the patient made a 
rapid recovery. Since surgery he has remained antibody positive but sutface 
antigen negative, and he is likely to be at low risk of recurrence. A 1.5-
year-old hemophiliac with chronic active hepatitis acquired as a complication 
of bctor VIII transfusions required liver transplantation for progressive 
cirrhosis. 10 After surgery he converted to an antigen-negative serology, and 
his new liver is making normal amounts of factor VIII. The liver transplant, 
which was performed for cirrhosis, may have cured his hemophilia. Longer 
follow-up is needed to assess the risk of recurrent hepatitis. 
Because there have been no specific markers for non A, non B hepatitis, 
it is difficult to assess the risk of recurrence in this group of patients. Two 
patients developed what may have been an acute episode of hepatitis, but 
both recovered. In general, results in this group of patients have been 
encouraging, and transplantation should be performed before disabling 
complications set in. 
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PRIMARY BILIARY CIRRHOSIS 
Primary biliary cirrhosis (PBC) is a chronic, nonsuppurative, destruc-
tive cholangitis of unknown etiology. 7. 17 It is an uncommon but not rare 
disorder that most often afflicts middle-aged women. The disease is asso-
ciated with a variety of immunologic ahm;rmalities and is considered to be 
an autoimmune disorder. 6. 32 A variety of other diseases have been reported 
in association with PBC, including scleroderma, rheumatoid arthritis, 
thyroiditis, interstitial pneumonitis, lupus erythematosus, renal tll hular 
acidosis, Sjogren's syndrome, and non-Hodgkin's lymphomas. 
PBC usually presents as jaundice, fatigue, pruritis, and hepatomegaly 
in middle-aged women. Laboratory studies show cholestasis and positive 
antimitochondrial antibodies. Liver biopsy shows degeneration or necrosis 
of interlobular bile ducts, granulomas, and mononuclear cell infiltrates. 
Metabolic bone disease is a common and serious complication of the disease. 
A variety of medical treatments have been tried to control this disease. 
The most extensive experience has been with D-pencillamine, II but recently 
chlorambucil, colchicine, and cyclosporine have been introduced in clinical 
trials. Although clinical trials are continuing, results of drug therapy have 
been disappointing and haw had little effect on survival. 
Thirty-nine patients have received livcr transplants for PBC. Most 
have been women in the fifth or sixth decade of life who had severe 
jaundice, ascites, esophageal varices, and advanced bone disease. An 
increase in the progression of jaundice, recurrent bleeding from esophageal 
varices, recurrent encephalopathy, and severe hepatic osteomalacia are the 
usual reasons for referral to the transplant center. Operation is often not 
technically difficult in these patients. since most have had minimal pre\'ious 
surgery and the large liver can be easy to remove. However, the advanced 
age and debilitated state of many of these patients complicate postoperative 
recovery. Disabling bone disease may result in a long, difficult recuperation. 
Actuarial survivals at 1 and 5 years are both 64.1 per cent (Fig. 8). 
Twenty-four patients are now living 1 to 6 years after transplantation, and 
there have been no patient deaths beyond 6 months after transplantation. 
Most patients' antimitochondrial antibody titers remain positive after trans-
plantation. It is difficult to distinguish histologically chronic allograft rejec-
tion from PBC. However, so far no case of recurrent PBC has been 
conclusively documented in any of the patients with transplants, in contrast 
to the experience of Neuberger and colleagues1.3 of Cambridge. 
In the absence of effeeti\'e medical therapy, liver transplantation is the 
treatment of choice for patients entering the advanced stages of primary 
hiliary cirrhosis. Referral to the transplant center before the patient becomes 
severely debilitated and avoidance of unnecessary abdominal surgery, 
especially in the right upper quadrant, can optimize the chances of 
successful transplantation. Operation for diagnosis is inappropriate. 
SCLEROSING CHOLANGITIS 
Sclerosing cholangitis is a chronic, cholestatic disease of unknown 
etiology. 1. Hll It is characterized by inflammation and fibrosis of the biliary 
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Figure 8. Actuarial (life table) survival is shown for 39 patients receiving liver transplants 
with cyclosporine and prednisone for primary biliary cirrhosis. Advanced age has not inflnenced 
survival in this group of patients but may prolong recuperation. 
system. Although the disease may localize to selected portions of the 
intrahepatic or extrahepatic biliary tree, sclerosing cholangitis is often a 
diffuse process. Liver biopsy demonstrates bile duct proliferation, periductal 
fibrosis and inflammation, ductal obliteration, and loss of bile ducts. 
Sclerosing cholangitis may occur as a primary disease or in association 
with other disorders, especially inflammatory bowel disease. There is strong 
evidence that sclerosing cholangitis is a premalignant condition that predis-
poses to the development of bile duct cancer. 
Sclerosing cholangitis is an incurable and eventually fatal disease. 
MedIcal treatment is aimed mainly at the control of complications. Surgery 
for sclerosing cholangitis is indicated only in special circumstances. Oper-
ation for diagnosis is unnecessary, except when differentiation of sclerosing 
cholangitis from adenocarcinoma of the bile duct cannot be accomplished 
by other means. Operative biliary diversion and drainage procedures should 
be limited to selected patients with well-localized extrahepatic disease. 
Percutaneous biliary decompression is no\v the procedure of choice for 
most patients with localized obstructions. Biliary tract surgery has little to 
offer the patient with diffuse disease and can complicate liver replacement. 
The early experience with liver transplantation in these patients suffered 
because many patients had been subjected to multiple operations to treat 
extrahepatIc biliary obstructions and because referral for transplantation 
was often delayed until patients were moribund from hepatic failure. 
Survival after liver transplantation for sclerosing cholangitis has im-
proved. Thirty patients have now received transplants for this disease with 
1- and 5- year actuarial survivals of 69.1 per cent (Fig. 9). Twenty-one 
patients are alive 6 months to 5 years after surgery, and therc have been 
no deaths beyond 1 year after transplantation. 
Selection of patients with sclerosing cholangitis requires careful indi-
vidualization. Duct cell tumors must be considered, especially in patients 
presenting with primary sclerosing cholangitis or a long history of the 
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Figure 9. Actuarial (life table) survival is s~own for 30 patients receiving liver transplants 
for sclerosing cholangitis and 16 patients receiving transplants for primary liver malignancies. 
disease. Patients with colitis are at increased risk of developing colonic 
malignancy when under immunosuppression after liver transplantation. 
Whenever indicated, proctocolectomy should be deferred for 3 to 6 months 
after liver replacement. The risk of recurrence of sclerosing cholangitis and 
the risk of bile duct cancer after transplantation are not yet known. 
PRIMARY LIVER MALIGNANCY 
The earliest liver transplants using conventional immunosuppression 
were performed for liver tumors that could not be removed by conventional 
hepatic resection. These patients are usually excellent operative candidates, 
and early survival after transplantation has been good. However, recurrence 
of tumor within 1 year of liver transplantation has been high, resulting in 
a high patient mortality,"o 
Thirty-six patients with primary hepatic malignancy have been treated 
by transplantation. Twenty of these patients were treated before the 
introduction of cyclosporine. Only 6 patients survived beyond 6 months, 
and all but one died within 54 months. All 19 patients lost had metastatic 
disease at the time of death. The lone survivor was originally thought to 
have a sarcoma of undertermined histologic type with miliary metastatic 
lesions at the time of transplantation. She is alive 8 years later, with no 
e\idence of acti\e tumor growth. He-examination of her tumor years later 
has led to a revised diagnosis of low-grade malignancy, if it is malignant at 
all. I""> 
Sixteen patients with transpiants received cyclosporine (Fig. 9). Only 
seven patients are living. Two surviving patients have known recurrences, 
and a third patient. now seven months hom operation. had residual tumor 
ill regional lymph nodes. 
There are two exceptions to the generally grim prognosis in this group 
of cancer patients treated with transplantation. First, 12 of 13 patients 
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received transplants for primary liver tumors incidental to other causes of 
end-stage liver disease have survived from 4 months to more than 15 years 
since transplantation. Second, six of the seven patients with the fibrolamellar 
variant of hepatocellular cancer16 have survived for more than 1 year. 
Metastases have developed in 4 of the 6 patients, two of whom have died. 
The two patients living with known recurrent fibrolamellar tumors have 
been followed for 19 and 38 months. Liver transplantation offers more 
effective palliation and possible cure in the patient with this variant of liver 
cancer. 
Generally, our experience with primary hepatic cancer has been 
disappointing and suggests that liver transplantation must be combined 
with other therapeutic modalities to offer effective treatment to most 
patients with this illness. 5 
MISCELLANEOUS DISEASES 
Seven patients with Budd-Chiari syndrome have received transplants. 
One patient on azathioprine and three patients on cyclosporine have 
survived. Two other patients survived 16 and 20 months after transplanta-
tion. One died following retransplantation for chronic rejection, and the 
other died of recurrence after anticoagulation was interrupted in preparation 
for a liver biopsy. Two of the three surviving patients required extensive 
thromboembolectomy of the vena cava and iliofemoral systems or of the 
portal vein at the time of transplantation, and all three patients have been 
maintained on permanent anticoagulation with Coumadin. 
Of nine patients who received transplants for familial cholestasis, seven 
have survived 6 months t 0 4 years after operation. The two deaths occurred 
within 3 months of transplantation. Four patients received transplants for 
neonatal hepatitis. All are surviving 6 months to 4 years after surgery. 
Only three patients with alcoholic cirrhosis have undergone transplant 
operations since the introduction of cyclosporine. Two died on the operating 
table. We have been reluctant to perform transplantation in this group of 
patients because of the long waiting list of candidates with non-self-inflicted 
diseases who are much better risks for surgery and because of the difficulty 
in determining which patients have truly reformed their lifestyles. How-
ever, increasing numbers of patients with alcoholic cirrhosis will be treated 
with liver replacement. 
RETRANSPLANTATION 
Twenty-one liver retransplantations were done using conventional 
immunosuppression with azathioprine. 5 Only four patients lived more than 
6 months, and all were dead within 14 months of retransplantation. 
About 20 per cent of the patients who undergo liver transplantation 
will require another transplant. 19 Sixty-eight patients have undergone a 
second transplantation from March 1, 1980, through December 31, 1984. 
Thirty-one patients are living (Fig. 10). As with primary transplants, survival 
has been better in children than in adults (Fig. U). 
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Figure 10. Indications for liver retransplantation. Eighty liver retransplantations were 
performed using cyclosporine and prednisone between March 1, i980, and December 31, 
1984. Sixty-eight patients received a second liver transplant, and 12 patients received a third 
liver transplant. Rejection was the most common reason for retransplantation (58.8 per cent). 
The indication for retransplantation has a definite bearing on survival 
(Fig. 12). Patients requiring retransplantation for primary graft failure 
decompensate rapidly, and retransplantation must be done urgently. Only 
2 of the 13 patients requiring a second graft for primary nonfunction of a 
first transplant have survived. On the other hand, 21 of39 patients requiring 
a second graft for rejection and 8 of 16 patients requiring a second graft for 
technical complications have survived. 
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Figure 11. Actuarial survival (life table method) after retransplantation with cyclosporine 
and prednisone from March 1, 1980, to December 31, 1984. Survival is better in children 
than in adults. Fifteen (39.5 per cent) of the 38 adults receiving retransplantations are surviving 
compared with 22 (52.4 per cent) of the 42 children. 
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Figure 12. Actuarial survival after liver retransplantation based on indication for graft 
replacement from March 1, 1980, to December 31, 1984. Over one half of the patients 
receiving retransplantations for rejection and nearly one half of those with retransplantations 
because of technical failure are surviving. Retransplantation for primary graft failure has had 
a high mortality rate. 
Technical complications requiring a second graft are more common in 
children (38.2 per cent) than in adults (8.8 per cent). Hepatic artery 
thrombosis accounts for nearly all technical problems requiring retransplan-
tation. It usually presents in one of three clinical patterns: fulminant liver 
failure (acute hepatic gangrene), delayed biliary leak (bile duct necrosis), 
or relapsing bacteremia. 33 Patients presenting with hepatic gangrene or bile 
duct necrosis require retransplantation, as do most patients with relapsing 
bacteremia who develop liver abscess. However, a small number of children 
appear to tolerate hepatic artery thrombosis without development of liver 
abscess and can be sustained with antibiotics until enough arterial collaterals 
develop. This small group of patients does not require retransplantation. 
About 10 per cent of patients will have an accelerated form of rejection. 
These patients may require urgent retransplantation. Most of the time, 
however, rejection is a gradual process, and retransplantation can be done 
under semielective conditions. Survival after retransplantation for rejection 
of a first graft has been good. Twenty-one of the 39 (53.8 per cent) requiring 
retransplantation for rejection of the first graft have survived. 
Twelve patients have required a third transplant. Six of these patients 
have survived. Five of the six patients who rejected both a first and a 
second transplant have survived aftcr a third transplant. 
Successful retransplantation with cyclosporine in nearly 50 per cent of 
the patients needing such treatment has contributed significantly to the 
improved results now being achieved. However, retransplantation adds 
greatly to the cost of care. The average hospital cost from 1983 to 1984 for 
pediatric liver transplant patients who required only one graft was about 
$85,000. The average hospital cost for pediatric patients requiring retrans-
plantation was nearly $200,000. 20 
-----------
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CONCLUSION 
Liver transplantation is now the treatment of choice for a variety of 
diseases leading to irrevcrsible liver failure in children and adults. Immu-
nosuppressive therapy based on cyclosporine-prednisone has tipped the 
scales more than any other bctor, but improvements in organ procurement 
techniques and in the recipient operation have also contributed. 
The extent to which patient selcction can influence results of trans-
plantation is hard to assess. As results have improved, there is increased 
justification for avoidance of invasive and less effective alternative treat-
ments and for earlier referral of patients to the transplant center. It is also 
clear that liver transplantatioll is of limited, if any, benefit for most patients 
with primary hepatic malignancy and for moribund patients in the terminal 
phase of advanced liver failure. 
Liver transplantation is costly, and the supply of donor organs is less 
than the demand fi)]" them. Should prioritization of candidates for liver 
transplantation be based on the probability of success or on the urgency of 
need? Except at extreme ends of the spectrum, it is difficult now to quantify 
risk. Shaw and colleagues22 recently assessed risk factors in a series of US 
adults who received primary orthotopic liver transplants using a scoring 
system designed to distinguish high-risk patients from low-risk patients. A 
sigmoid curve was found to best describe the relationship between risk 
score and patient survival. Since many of thc patients were found to havc 
scores falling between the inflection points of the curve, it was difficult for 
most patients to predict the likelihood of success based on perioperative 
assessment of risk. Many paticnts who might scem to be at high risk have 
an excellent chance for survival in the hands of a skilled transplant team. 
Given the uncertainties of predicting outcome based on risk, we 
continue to select patients for liver transplantation based on the urgency of 
need but with congnizance of those extreme circumstances in which 
transplantation would be wasteful and inappropriate. This places us under 
constant pressure not to ncglect the progression of illness in patients who 
have acerucd months of waiting on the candidate list and enables us to 
offer transplantation on a basis that physicians, patients, families, and the 
general public can accept as equitable. 
SUMMARY 
One hundred seventy orthotopic liver transplants were performed 
under conventional immunosuppression with azathioprine and steroids with 
1- and 5-year survivals of :32.9 per cent and 20.0 per cent, respectively. 
Since the introduction of cyclosporiue-prednisone therapy in March 1980, 
:31:3 primary orthotopic liver transplants have been performed. Actuarial 
survivals at 1 and 5 years have improved to 69.7 per cent and 62.S per 
cent, respectively. 
Biliary atrcsia is now the most common indication for liver replacement. 
In adults, primary biliary cirrhosis and sclerosing cholangitis have become 
more common indications for transplantation, and alcoholic cirrhosis and 
primary liver malignancy as indications have declined. Early enthusiasm 
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for liver transplantation in patients with hepatic cancer has been tempered 
by the finding that recurrence is both common and rapid. An increasing 
number of patients with inborn errors of metabolism originating in the liver 
are receiving transplants, including patients with Wilson's disease, tyrosi-
ncmia, alpha-I-antitrypsin dcficiency, glycogen storage disease, familial 
hypercholesterolemia, and hemochromatosis. Survival in this group of 
patients has been excellent (74.4 per cent at 1 and 5 years). A hemophiliac 
who received a transplant for postnecrotic cirrhosis has survived and mav 
have been cured of his hemophilia. . 
About 20 per cent of patients require retransplantation for rejection, 
technical failure, or primary graft failure. Only four of the patients receiving 
retransplants under conventional immunosuppression survived beyond 6 
months, and all died within 14 months of retransplantation. Sixty-eight 
patients have received retransplants under cyclosporine-prednisone. Thirty-
one patients are surviving, all for at least 1 year. Six of the twelve patients 
requiring a third transplant are alive 2 to 3 years after the primary operation. 
An aggressive approach to retransplantation in the patient with a failed 
graft is justified. 
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